# US 2024/0199612 A1 · Imidazopyridinyl inhibitors of plasma kallikrein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199612 A1
- Document ID: US20240199612A1
- Status: Published application
- Kind: A1
- Application number: 18/550,474
- Filed: 2022-03-16
- Published: 2024-06-20
- Earliest claimed: 2021-02-23
- Assignees: Shire Human Genetic Therapies, Inc.
- Applicants: Shire Human Genetic Therapies, Inc.
- Inventors: Nikolaos PAPAIOANNOU; Jeremy Mark TRAVINS; Sarah Jocelyn FINK; John Mark ELLARD; Alastair RAE
- Web page: https://patentgrep.com/patent/US20240199612A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/506: not condensed and containing further heterocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
CyA is a phenylene or 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyA is substituted with 0-4—RA groups;
each RA is independently selected from oxo, halogen, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
each R is independently hydrogen or an optionally substituted C1-6 aliphatic group;
CyB is selected from phenyl, 8- to 10-membered bicyclic aryl, 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur or 7- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyB is substituted with 0-5 —RB groups;
each RB is independently selected from oxo, halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or a 5- to 6-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
L is an optionally substituted C1-3 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O—, —NRz—, —S—, —SO—, or —SO2—; or L is an optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclene, having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
each Rz is independently selected from hydrogen, —(CH2)0-3OR, —(CH2)0-3C(O)OR, or an optionally substituted C1-6 aliphatic group;
X is —O— or —NRy—;
Ry is hydrogen or an optionally substituted C1-6 aliphatic group;
L′ is a covalent bond or an optionally substituted C1-3 hydrocarbon chain, wherein a carbon of L′ may optionally be taken together with Ry to form a 3- to 7-membered heterocyclic ring;
each R3, R4, R5, R6, and R7 is independently selected from hydrogen or -LC-RC, wherein
each LC is independently selected from a covalent bond or an optionally substituted C1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O— or —NR—;
each RC is independently selected from halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, CyC, or an optionally substituted group selected from C1-6 aliphatic;
each CyC is independently selected from a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, a 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 6- to 12-membered saturated or partially unsaturated fused bicyclic heterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, a bridged bicycle, or a 6- to 12-membered saturated or partially unsaturated bicyclic spiroheterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein CyC is substituted with 0-4 -LD-RD groups;
each LD is independently selected from a covalent bond or an optionally substituted C1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O— or —NR—;
each RD is independently selected from oxo, halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R,
—OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; and
R8 is selected from hydrogen, —OR, or an optionally substituted C1-6 aliphatic group.

### Claim 2 (depends on 1)

The compound of claim 1, wherein CyA is a 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyA is substituted with 0-4—RA groups.

### Claim 3 (depends on 1)

The compound of claim 1, wherein CyA is selected from the group consisting of:
wherein * represents the point of attachment to L.

### Claim 4 (depends on 1)

The compound of claim 1, wherein CyA is a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyA is substituted with 0-4—RA groups.

### Claim 5 (depends on 1)

The compound of claim 1, wherein CyA is triazolopyridinediyl, imidazopyridinediyl, or triazolopyrazinediyl, wherein CyA is substituted with 0-1 —RA groups.

### Claim 6 (depends on 1)

The compound of claim 1, wherein CyB is selected from phenyl and a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyB is substituted with 0-4 —RB groups.

### Claim 7 (depends on 1)

The compound of claim 1, wherein CyB is selected from the group consisting of:

### Claim 8 (depends on 1)

The compound of claim 1, wherein each RB is independently selected from halogen, —OR, or an optionally substituted group selected from C1-6 aliphatic or a 5-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur.

### Claim 9 (depends on 1)

The compound of claim 1, wherein L is an optionally substituted C1-3 hydrocarbon chain, wherein 1 methylene unit is optionally replaced with —O— or —NRz—.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L is *—NHCH2— or *—OCH2—, wherein * represents the point of attachment to CyA.

### Claim 11 (depends on 1)

The compound of claim 1, wherein L is an optionally substituted 5-membered saturated or partially unsaturated heterocyclene, having 1 heteroatom independently selected from oxygen, nitrogen, and sulfur.

### Claim 12 (depends on 1)

The compound of claim 1, wherein L′ is an optionally substituted C1-3 hydrocarbon chain.

### Claim 13 (depends on 1)

The compound of claim 1, wherein L′ is, —CH(CH3)—, CH2,
wherein * represents the point of attachment to CyB.

### Claim 14 (depends on 1)

The compound of claim 1, wherein a carbon of L′ may optionally be taken together with Rz to form a 3- to 7-membered heterocyclic ring.

### Claim 15 (depends on 1)

The compound of claim 1, wherein a carbon of L′ is taken together with Ry to form a 4-membered heterocyclic ring.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R4 is hydrogen

### Claim 18 (depends on 1)

The compound of claim 1, wherein R5 is hydrogen.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R6 is selected from hydrogen or LC-RC, wherein LC is a covalent bond, and wherein RC is selected from halogen, —N(R)2, —OR, CyC, or an optionally substituted C1-6 aliphatic group.

### Claim 20 (depends on 1)

The compound of claim 1, wherein CyC is an unsubstituted cyclopropyl group.

### Claim 21 (depends on 1)

The compound of claim 1, wherein R7 is hydrogen.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is of Formulae II-a or II-b:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound is of Formulae III-a-1, III-b-1, III-a-2, III-b-2, III-a-3, or III-b-3:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is of Formulae IV-a-1, IV-b-1, IV-a-2, or IV-b-2:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The compound of claim 1, wherein the compound is of Formula V:
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is of Formulae VI-a, VI-b, or VI-c:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is selected from compounds I-1 through I-34, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1.

### Claim 29 (depends on 1)

A method of treating a plasma kallikrein-mediated disease or disorder using a compound of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, wherein the disease or disorder is hereditary angioedema or diabetic macular edema.
